[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
[ Mon, Feb 27th 2023 ]: WOPRAI
Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $79 on, Feb 27th, 2023
- 🞛 This publication is a summary or evaluation of another publication
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $79 on, Feb 27th, 2023.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, February 8th, 2023
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022